The main growth driver for Alkermes going forward will be ALKS 2680. Read why I maintain my buy rating on ALKS stock.

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

These homes are costing taxpayers an eye-watering amount, but behind closed doors they conceal disturbing scenes endured by ...

Suicide rates for schizophrenia are among the highest of any mental illness, but suicide prevention strategies can make a ...

Feb. 26, 2025 — The symptoms of schizophrenia vary greatly from person to person. A new study shows how these differences manifest themselves in the structure of the ... Genetic Risk of ...

Machine learning models trained on electronic health record data were able to successfully predict diagnostic progression to schizophrenia and bipolar disorder among patients with other mental ...

The U.S. Food and Drug Administration has removed one hurdle faced by patients with schizophrenia when filling prescriptions ...

The following is a summary of “Bioinformatics-based identification of CTSS, DOK2, and ENTPD1 as potential blood biomarkers of schizophrenia,” published in the February 2025 issue of BMC Psychiatry by ...

Fortune’s Term Sheet newsletter covers the latest news, insights, and analysis on private equity, venture capital, start-ups, mergers and acquisitions, high-value deals, and the dealmakers ...

A "chasm of misunderstanding and miscommunication" is often experienced between clinicians and patients, leading to ...

BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...